- $3.94bn
- $8.53bn
- $2.74bn
- 72
- 48
- 58
- 61
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 25.7 | ||
PEG Ratio (f) | 1.01 | ||
EPS Growth (f) | 34.05% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.02 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 19.31 | ||
Price to Sales | 1.36 | ||
EV to EBITDA | 18.62 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 4.97% | ||
Return on Equity | -1.7% | ||
Operating Margin | 11.93% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 1,831.4 | 1,860.1 | 2,225.1 | 2,539.3 | 2,743.3 | 3,085.07 | 3,377.84 | 9.14% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +103.87 | +19.85 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. Its segments include Surgical Facility Services and Ancillary Services. The Surgical Facility Services segment consists of the operation of ASCs and surgical hospitals and includes its anesthesia services. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology and general surgery. The Ancillary Services segment consisted of multi-specialty physician practices, including physician practices owned and operated pursuant to long-term management service agreements. It is focused on surgical services businesses in the United States, with over 180 locations in 33 states, including ambulatory surgery centers, short-stay surgical hospitals, and multi-specialty physician practices.
Directors
- Wayne DeVeydt CHM (51)
- J. Eric Evans CEO (44)
- David Doherty CFO (49)
- George Goodwin CEX (60)
- Bradley Owens CEX (51)
- Laura Brocklehurst CHO (51)
- Jennifer Baldock EVP (50)
- Anthony Taparo OTH (55)
- Clifford Adlerz DRC (67)
- Blair Hendrix DRC
- T. Devin O'Reilly DRC (47)
- John Deane IND (59)
- Teresa DeLuca IND (55)
- Andrew Kaplan IND (36)
- Patricia Maryland IND (67)
- Brent Turner IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 2nd, 2015
- Public Since
- October 1st, 2015
- No. of Shareholders
- 179
- No. of Employees
- 10,500
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 127,123,940
- Address
- 310 Seven Springs Way Ste 500, BRENTWOOD, 37027-5679
- Web
- https://surgerypartners.com/
- Phone
- +1 6152345900
- Auditors
- Deloitte & Touche LLP
Upcoming Events for SGRY
Q4 2024 Surgery Partners Inc Earnings Release
Similar to SGRY
Acadia Healthcare
NASDAQ Global Select Market
Accolade
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
FAQ
As of Today at 23:59 UTC, shares in Surgery Partners are trading at $31.00. This share price information is delayed by 15 minutes.
Shares in Surgery Partners last closed at $31.00 and the price had moved by -3.67% over the past 365 days. In terms of relative price strength the Surgery Partners share price has underperformed the S&P500 Index by -23.8% over the past year.
The overall consensus recommendation for Surgery Partners is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSurgery Partners does not currently pay a dividend.
Surgery Partners does not currently pay a dividend.
Surgery Partners does not currently pay a dividend.
To buy shares in Surgery Partners you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $31.00, shares in Surgery Partners had a market capitalisation of $3.94bn.
Here are the trading details for Surgery Partners:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SGRY
Based on an overall assessment of its quality, value and momentum Surgery Partners is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Surgery Partners is $39.33. That is 26.87% above the last closing price of $31.00.
Analysts covering Surgery Partners currently have a consensus Earnings Per Share (EPS) forecast of $1.06 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Surgery Partners. Over the past six months, its share price has underperformed the S&P500 Index by -0.34%.
As of the last closing price of $31.00, shares in Surgery Partners were trading +6.59% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Surgery Partners PE ratio based on its reported earnings over the past 12 months is 25.7. The shares last closed at $31.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Surgery Partners' management team is headed by:
- Wayne DeVeydt - CHM
- J. Eric Evans - CEO
- David Doherty - CFO
- George Goodwin - CEX
- Bradley Owens - CEX
- Laura Brocklehurst - CHO
- Jennifer Baldock - EVP
- Anthony Taparo - OTH
- Clifford Adlerz - DRC
- Blair Hendrix - DRC
- T. Devin O'Reilly - DRC
- John Deane - IND
- Teresa DeLuca - IND
- Andrew Kaplan - IND
- Patricia Maryland - IND
- Brent Turner - IND